Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial

Sheikh, SZ; Scheinberg, MA; Wei, JCC; Tegzova, D; Stohl, W; de Toledo, RA; Mucenic, T; Banfi, MRA; Maksimowicz-McKinnon, K; Abud-Mendoza, C; Navarra, S; Garcia, M; Garcia-De La Torre, I; Ros, JO; Levy, RA; Bass, DL; Terres, JR; Punwaney, R; Harris, J; Nami, A; Pierce, A; Thorneloe, KS; Ji, B; Roth, DA

Sheikh, SZ (corresponding author), Univ N Carolina, Rheumatol Allergy & Immunol, Chapel Hill, NC 27599 USA.

LANCET RHEUMATOLOGY, 2021; 3 (2): E122

Abstract

Findings Between Nov 27, 2012, and July 28, 2017, we randomly assigned 4018 patients. The as-treated population included 2002 patients in the belimuma......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索